Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2431
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital ; volume:22 ; number:1 ; day:12 ; month:1 ; year:2022 ; pages:1-9 ; date:12.2022
BMC pediatrics ; 22, Heft 1 (12.1.2022), 1-9, 12.2022
- Creator
-
Bazargani, Behnaz
Noparast, Zahra
Khedmat, Leila
Fahimi, Daryoosh
Esfahani, Seyed Taher
Moghtaderi, Mastaneh
Abbasi, Arash
Afshin, Azadeh
Mojtahedi, Sayed Yousef
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12887-022-03109-4
- URN
-
urn:nbn:de:101:1-2022042618582605542213
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bazargani, Behnaz
- Noparast, Zahra
- Khedmat, Leila
- Fahimi, Daryoosh
- Esfahani, Seyed Taher
- Moghtaderi, Mastaneh
- Abbasi, Arash
- Afshin, Azadeh
- Mojtahedi, Sayed Yousef
- SpringerLink (Online service)
Other Objects (12)
Rituximab for nephrotic syndrome in children
Hypokalemia after rituximab administration in nephrotic syndrome: two case reports
Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
Rituximab is not a “magic drug” in post-transplant recurrence of nephrotic syndrome
A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome
High detection rate for disease-causing variants in a cohort of 30 Iranian pediatric steroid resistant nephrotic syndrome cases
Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey
The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective
Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome
Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
Difficult Renal Pathological Classification in a Case of Pediatric Nephrotic Syndrome
Iranian Intellectuals’ Experience of Modern Science
Rituximab for nephrotic syndrome in children
Hypokalemia after rituximab administration in nephrotic syndrome: two case reports
Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
Rituximab is not a “magic drug” in post-transplant recurrence of nephrotic syndrome
A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome
High detection rate for disease-causing variants in a cohort of 30 Iranian pediatric steroid resistant nephrotic syndrome cases
Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey
The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective
Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome
Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
Difficult Renal Pathological Classification in a Case of Pediatric Nephrotic Syndrome
Iranian Intellectuals’ Experience of Modern Science
Rituximab for nephrotic syndrome in children
Hypokalemia after rituximab administration in nephrotic syndrome: two case reports
Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
Rituximab is not a “magic drug” in post-transplant recurrence of nephrotic syndrome
A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome
High detection rate for disease-causing variants in a cohort of 30 Iranian pediatric steroid resistant nephrotic syndrome cases
Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey
The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective
Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome
Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
Difficult Renal Pathological Classification in a Case of Pediatric Nephrotic Syndrome